Volume 133, Issue 6



February 7, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Salmonella Typhimurium infection triggers thrombi that do not trap bacteria. See the article by Beristain-Covarrubias et al .

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study


Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
Two randomized studies compare the therapeutic efficacy of the new long-acting complement C5 inhibitor ravulizumab to that of eculizumab in patients with paroxysmal nocturnal hemoglobinuria who are treatment naive (the 301 study) and patients who are on eculizumab therapy (the 302 study).

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Koch and colleagues used BH3 profiling and patient-derived xenograft models to tailor potential synergistic therapies for T-cell lymphomas.

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
Edwards and colleagues report the contribution of signaling from support cells in the maintenance of acute myeloid leukemia, demonstrating that targeting CSF1 receptors on stromal cells in the niche yields antitumor activity.

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study
Monoclonal immunoglobulin deposition disease (MIDD) is an unusual presentation of B-cell clonal disorders characterized by prominent renal involvement. Joly and colleagues describe the clinical presentation and natural history of MIDD in a national cohort of 255 patients, emphasizing the high frequency of extrarenal disease manifestations.

Salmonella-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps
Infection can induce thrombi that have been postulated to trap bacteria and help control infection. Beristain-Covarrubias et al document sequential thrombus formation in the spleen and liver following Salmonella infection and demonstrate that, in fact, thrombi do not trap bacteria.

How I treat MDS after hypomethylating agent failure
Using 4 illustrative cases, Santini reviews the options for treating myelodysplastic syndromes after failure of hypomethylating agent therapy.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.